Cost-Effectiveness of Osteoporosis Interventions for 'Incidental' Vertebral Fractures

被引:10
作者
Majumdar, Sumit R. [1 ,2 ,3 ]
Lier, Douglas A. [1 ,3 ]
McAlister, Finlay A. [1 ,2 ]
Rowe, Brian H. [2 ,4 ]
Siminoski, Kerry [1 ]
Hanley, David A. [5 ]
Russell, Anthony S. [1 ]
Johnson, Jeffrey A. [2 ,3 ]
机构
[1] Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2B7, Canada
[3] Inst Hlth Econ, Edmonton, AB, Canada
[4] Univ Alberta, Dept Emergency Med, Edmonton, AB T6G 2B7, Canada
[5] Univ Calgary, Dept Med, Calgary, AB, Canada
基金
加拿大健康研究院;
关键词
Cost-effectiveness; Interventions; Osteoporosis; Quality improvement; Trials; POSTMENOPAUSAL OSTEOPOROSIS; ALENDRONATE; WOMEN; PREVENTION; MODEL;
D O I
10.1016/j.amjmed.2012.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Vertebral fractures detected "incidentally" by chest radiograph usually do not trigger osteoporosis treatment in older patients. In a 3-arm controlled trial we reported that both physician-directed and enhanced (physician plus patient activation) interventions increased treatment rates more than 10-fold (15%-20% absolute increases) compared with usual care; the cost-effectiveness of these interventions is unknown. METHODS: Incremental cost-effectiveness of these 2 interventions compared with usual care was assessed using a Markov decision-analytic model, populated with 1-year outcomes data and direct intervention costs from the trial. Costs were expressed in 2009 Canadian dollars and effectiveness based on quality-adjusted life years (QALYs) gained. The perspective was health care payer; horizon was projected lifetime; costs and benefits were discounted at 3%; and deterministic and probabilistic sensitivity analyses were conducted. RESULTS: Per patient, the physician and enhanced interventions cost $34 and $42, respectively. Compared with usual care, for every 1000 patients exposed to the physican intervention there were 4 fewer fractures, 8 more QALYs gained, and $282,000 saved. Compared with physician interventions, for every 1000 patients exposed to enhanced interventions there were 6 fewer fractures, 6 more QALYs gained, and $339,000 saved. Both interventions dominated usual care and were cost-effective in similar to 80% of 10,000 probabilistic simulations. Although the enhanced intervention cost $8 more per patient, it still dominated the physician intervention and usual care, and was the most economically attractive option. CONCLUSIONS: Pragmatic and inexpensive interventions directed at patients with incidentally detected vertebral fractures and their physicians are highly cost-effective at improving osteoporosis treatment, and in most circumstances also are cost-saving. (C) 2013 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2013) 126, 169.e9-169.e17
引用
收藏
页码:169.e9 / 169.e17
页数:9
相关论文
共 50 条
  • [31] Cost-effectiveness of osteoporosis treatments in postmenopausal women using FRAX™ thresholds for decision
    Alzahouri, Kazem
    Bahrami, Stephane
    Durand-Zaleski, Isabelle
    Guillemin, Francis
    Roux, Christian
    JOINT BONE SPINE, 2013, 80 (01) : 64 - 69
  • [32] Cost-Effectiveness of Dementia Prevention Interventions
    Ian McRae
    L. Zheng
    S. Bourke
    N. Cherbuin
    K. J. Anstey
    The Journal of Prevention of Alzheimer's Disease, 2021, 8 : 210 - 217
  • [33] A novel economic framework to assess the cost-effectiveness of bone-forming agents in the prevention of fractures in patients with osteoporosis
    Soreskog, E.
    Borgstrom, F.
    Lindberg, I.
    Strom, O.
    Willems, D.
    Libanati, C.
    Kanis, J. A.
    Stollenwerk, B.
    Charokopou, M.
    OSTEOPOROSIS INTERNATIONAL, 2021, 32 (07) : 1301 - 1311
  • [34] Cost-effectiveness research in osteoporosis
    Coyle, D
    Cranney, A
    Lee, KM
    Welch, V
    Tugwell, P
    DRUG DEVELOPMENT RESEARCH, 2000, 49 (03) : 135 - 140
  • [35] The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAXA®
    Borgstrom, F.
    Strom, O.
    Coelho, J.
    Johansson, H.
    Oden, A.
    McCloskey, E. V.
    Kanis, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (03) : 495 - 505
  • [36] A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis
    Hiligsmann, Mickael
    Evers, Silvia M.
    Ben Sedrine, Wafa
    Kanis, John A.
    Ramaekers, Bram
    Reginster, Jean-Yves
    Silverman, Stuart
    Wyers, Caroline E.
    Boonen, Annelies
    PHARMACOECONOMICS, 2015, 33 (03) : 205 - 224
  • [37] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Strom, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 967 - 982
  • [38] Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis
    Andrew J. Rosner
    Daniel T. Grima
    George W. Torrance
    Cathy Bradley
    Jonathan D. Adachi
    Rolf J. Sebaldt
    Donald J. Willison
    PharmacoEconomics, 1998, 14 : 559 - 573
  • [39] Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United States
    Reginster, Jean-Yves
    Silverman, Stuart L.
    Alokail, Majed
    Al-Daghri, Nasser
    Hiligsmann, Mickael
    JBMR PLUS, 2024, 9 (01)
  • [40] Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients
    Morizio, Paige
    Burkhart, Jena I.
    Ozawa, Sachiko
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (10) : 1031 - 1041